Kombination von Obefazimod und Seinen Derivaten mit einem ALPHA4BETA7-Integrin
EP4785941
5. August 2026
Anmelder: ABIVAX 🇫🇷
Details
- Veröffentlichungs-Nr.
- EP4785941
- Anmeldetag
- 31. Januar 2025
- Veröffentlichung
- 5. August 2026
- Rechtsraum
- EP
Abstract
The present invention relates to pharmaceutical combinations, pharmaceutical compositions, kits comprising a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and a α4β7 anti-integrin. The present invention also relates to said pharmaceutical combination for use in the treatment of an inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula: <img class="EMIRef" id="bd65077d-5055-4084-8e95-b80a64655264-ia01" />
Anmelder
- Firma
- ABIVAX
- Land
- 🇫🇷 Frankreich